Skip to main content
NCBI home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1998 Mar;51(3):220–224. doi: 10.1136/jcp.51.3.220

Omeprazole may exert both a bacteriostatic and a bacteriocidal effect on the growth of Helicobacter pylori (NCTC 11637) in vitro by inhibiting bacterial urease activity.

F Mirshahi 1, G Fowler 1, A Patel 1, G Shaw 1
PMCID: PMC500643  PMID: 9659264

Abstract

AIMS: To assess the potential antibacterial effect of omeprazole, a benzimidazole proton pump inhibitor, on the growth of Helicobacter pylori in vitro and to evaluate the effect of this compound on bacterial urease activity. METHODS: The growth of H pylori was observed in liquid culture in the presence and absence of omeprazole (0.8 mg/ml). Urease activity was evaluated in aliquots removed from two hour cultures by monitoring the initial change in absorbency at 560 nm in the presence of 0.02% phenol red. RESULTS: The minimum inhibitory concentration of omeprazole against H pylori was 0.8 mg/ml. The concentration of omeprazole required to inhibit growth was dependent on inoculum density: omeprazole (0.8 mg/ml) prevented growth from a 1 x 10(6) cfu/ml inoculum, but not from the higher inocula of 10(7) or 10(8) cfu/ml. This is the first study to demonstrate that omeprazole exerts a bacteriocidal effect against low bacterial densities and a bacteriostatic effect when bacterial density is high. When used at the onset of growth, this concentration of omeprazole has a bacteriocidal effect after four hours, although it exerts a bacteriostatic effect when added to cultures after the exponential phase. Bacterial urease activity is competitively inhibited by omeprazole in a dose dependent manner. CONCLUSION: The results suggest that omeprazole exerts both a bacteriocidal and a bacteriostatic effect against H pylori and competitively inhibits bacterial extracellular urease activity.

Full text

PDF
220

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. An international association between Helicobacter pylori infection and gastric cancer. The EUROGAST Study Group. Lancet. 1993 May 29;341(8857):1359–1362. [PubMed] [Google Scholar]
  2. Coghlan J. G., Gilligan D., Humphries H., McKenna D., Dooley C., Sweeney E., Keane C., O'Morain C. Campylobacter pylori and recurrence of duodenal ulcers--a 12-month follow-up study. Lancet. 1987 Nov 14;2(8568):1109–1111. doi: 10.1016/s0140-6736(87)91545-5. [DOI] [PubMed] [Google Scholar]
  3. Eaton K. A., Brooks C. L., Morgan D. R., Krakowka S. Essential role of urease in pathogenesis of gastritis induced by Helicobacter pylori in gnotobiotic piglets. Infect Immun. 1991 Jul;59(7):2470–2475. doi: 10.1128/iai.59.7.2470-2475.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Figura N., Crabtree J. E., Dattilo M. In-vitro activity of lansoprazole against Helicobacter pylori. J Antimicrob Chemother. 1997 May;39(5):585–590. doi: 10.1093/jac/39.5.585. [DOI] [PubMed] [Google Scholar]
  5. Goodwin C. S., Armstrong J. A., Marshall B. J. Campylobacter pyloridis, gastritis, and peptic ulceration. J Clin Pathol. 1986 Apr;39(4):353–365. doi: 10.1136/jcp.39.4.353. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. HOLLANDER F. The two-component mucous barrier; its activity in protecting the gastroduodenal mucosa against peptic ulceration. AMA Arch Intern Med. 1954 Jan;93(1):107–120. doi: 10.1001/archinte.1954.00240250117009. [DOI] [PubMed] [Google Scholar]
  7. Iwahi T., Satoh H., Nakao M., Iwasaki T., Yamazaki T., Kubo K., Tamura T., Imada A. Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori. Antimicrob Agents Chemother. 1991 Mar;35(3):490–496. doi: 10.1128/aac.35.3.490. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Kühler T. C., Fryklund J., Bergman N. A., Weilitz J., Lee A., Larsson H. Structure-activity relationship of omeprazole and analogues as Helicobacter pylori urease inhibitors. J Med Chem. 1995 Dec 8;38(25):4906–4916. doi: 10.1021/jm00025a008. [DOI] [PubMed] [Google Scholar]
  9. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  10. Mainguet P., Delmée M., Debongnie J. C. Omeprazole, campylobacter pylori, and duodenal ulcer. Lancet. 1989 Aug 12;2(8659):389–390. doi: 10.1016/s0140-6736(89)90569-2. [DOI] [PubMed] [Google Scholar]
  11. Midolo P. D., Turnidge J. D., Lambert J. R. Bactericidal activity and synergy studies of proton pump inhibitors and antibiotics against Helicobacter pylori in vitro. J Antimicrob Chemother. 1997 Mar;39(3):331–337. doi: 10.1093/jac/39.3.331. [DOI] [PubMed] [Google Scholar]
  12. Morgan D. R., Freedman R., Depew C. E., Kraft W. G. Growth of Campylobacter pylori in liquid media. J Clin Microbiol. 1987 Nov;25(11):2123–2125. doi: 10.1128/jcm.25.11.2123-2125.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Rauws E. A., Langenberg W., Bosma A., Dankert J., Tytgat G. N. Lack of eradication of Helicobacter pylori after omeprazole. Lancet. 1991 May 4;337(8749):1093–1093. doi: 10.1016/0140-6736(91)91737-f. [DOI] [PubMed] [Google Scholar]
  14. Rauws E. A., Tytgat G. N. Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet. 1990 May 26;335(8700):1233–1235. doi: 10.1016/0140-6736(90)91301-p. [DOI] [PubMed] [Google Scholar]
  15. Sjöström J. E., Fryklund J., Kühler T., Larsson H. In vitro antibacterial activity of omeprazole and its selectivity for Helicobacter spp. are dependent on incubation conditions. Antimicrob Agents Chemother. 1996 Mar;40(3):621–626. doi: 10.1128/aac.40.3.621. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES